TIGIT - HEK293 Recombinant Cell Line
Catalog #
79332
$4,400
*
●
●
Purchase
Description
Recombinant HEK293 stably expressing human TIGIT (T cell immunoreceptor with Ig and ITIM domains; VSTM3; VSIG9), GenBank Accession #NM_173799.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
●
Synonyms
Immunotherapy, T cell immunoreceptor with Ig and ITIM domains, HEK293
●
Product Data Gallery
Product Info
Storage and Usage
Citations
Host Cell Line
HEK293 cells
Supplied As
Each vial contains ~3 X 106 cells in 1 ml of 10% DMSO.
Materials Required But Not Supplied
Genbank #
NM_173799
UniProt #
Q495A1
Mycoplasma Testing
The cell line has been screened using the metabolite-based Mycoplasma Detection Kit (Biotool, #B3903) to confirm the absence of Mycoplasma species.
Background
TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies.